Hospira applauds NICE for issuing adoption resource to help drive the introduction of biosimilars

August 14, 2015 7:21 AM

Hospira, Inc. applauds the UK’s National Institute for Health and Clinical Excellence (NICE) for developing and issuing a new adoption resource to further support the introduction of biosimilar infliximab, including Hospira’s Inflectra, allowing patients greater access to these expensive treatments and greater choice for physicians.

The recently published adoption resource entitled, “Introducing biosimilar versions of infliximab: Inflectra and Remsima,” provides practical advice on how to effectively introduce biosimilars into clinical practice, as well as a process to implement a well-managed and safe switching program from reference biologics to biosimilars. Through case studies, the resource highlights how biosimilars can help lead to a more sustainable healthcare system and can help improve patient access to high cost biologic medicines.

This new resource underlines the opportunities for cost-savings and re-investment, stating that “the use of biosimilars can reduce costs, allowing more treatment with new medicines as long as the appropriate follow-up and monitoring systems are in place to manage risk and patient needs and expectations.” According to NICE, “Biosimilars have the potential to offer the NHS considerable cost savings, especially as biological medicines are often expensive and are often used to treat long-term conditions.”

This reinvestment offers a new basis for sustainable healthcare through “close collaboration and trust between clinicians, hospital management and CCGs, with all parties being appropriately incentivised to deliver high quality patient care and cost savings.”

Since launching the first biosimilar monoclonal antibody, Inflectra in the UK in February 2015, Hospira has continued to work with payers and clinicians in supporting the introduction of Inflectra into their care pathways safely and effectively.

“Inflectra continues to provide an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product,” said Paul Greenland, vice president, Biologics, Hospira.

Hospira is the only U.S.-based company currently marketing biosimilars in the highly regulated markets of Europe and Australia, where we have seen biosimilars help to decrease the costs of biologics by 20 to 30 percent. This has allowed European healthcare systems to reduce their healthcare spending, while at the same time increasing patient access to these important biologic medicines.

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!